CDKN2A and neoplasm: According to more recent next-generation sequencing studies, mutations in the BRAF gene are associated with mutated up- or downstream molecules which act as tumor suppressors, e.g., cyclin-dependent kinase inhibitor 2A (CDKN2A) (p16, p14ARF), TP53, and phosphatase and tensin homolog (PTEN) [4,5].